We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+11.58%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$196M
(+8.3%)
Cap. Flow
-$299M
Cap. Flow
% of AUM
-11.74%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
126
New
21
Increased
16
Reduced
23
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADPT
Adeptus Health Inc
ADPT
|
+$38.6M |
| 2 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$38M |
| 3 |
DBVT
DBV Technologies
DBVT
|
+$30M |
| 4 |
Humana
HUM
|
+$28.3M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$26.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$67.9M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$35.7M |
| 3 |
McKesson
MCK
|
+$27.5M |
| 4 |
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
|
+$27.4M |
| 5 |
AET
Aetna Inc
AET
|
+$25.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.67% |
| 2 | Financials | 3.21% |
| 3 | Industrials | 0.75% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTN
101
Palatin Technologies
PTN
$16.2M
| – | – |
-789
| Closed | -$532K |
|
|
SAGE
102
DELISTED
Sage Therapeutics
SAGE
| – | – |
-1,113,654
| Closed | -$35.7M |
|
103
Tonix Pharmaceuticals
TNXP
$198M
| – | – |
0
| – | -$3.17M |
|
104
Trupanion
TRUP
$1.16B
| – | – |
-155,236
| Closed | -$1.53M |
|
105
Veracyte
VCYT
$4.72B
| – | – |
-165,097
| Closed | -$892K |
|
|
ABMD
106
DELISTED
Abiomed Inc
ABMD
| – | – |
-49,797
| Closed | -$4.72M |
|
|
XLRN
107
DELISTED
Acceleron Pharma
XLRN
| – | – |
-353,491
| Closed | -$9.33M |
|
|
WMGI
108
DELISTED
Wright Medical Group Inc
WMGI
| – | – |
-30,000
| Closed | -$498K |
|
|
AGN
109
DELISTED
Allergan plc
AGN
| – | – |
-3,500
| Closed | -$938K |
|
|
ADYX
110
DELISTED
Adynxx Inc
ADYX
| – | – |
-11,121
| Closed | -$547K |
|
|
ELGX
111
DELISTED
Endologix Inc
ELGX
| – | – |
-56,990
| Closed | -$4.76M |
|
|
IMPR
112
DELISTED
IMPRIVATA, INC COM
IMPR
| – | – |
-983,366
| Closed | -$12.4M |
|
|
HTWR
113
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| – | – |
-870,634
| Closed | -$27.4M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2016 Portfolio in Review
As of Q2 2016, Deerfield Management held 126 positions worth $2.54B, up 8.3% from $2.35B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $299M in Q2 2016, closing 19 positions and reducing 23 holdings. Its most notable exit was GSK, an estimated $67.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials and Industrials.
Against the trend, Deerfield Management opened a new position in Syros Pharmaceuticals, Inc. Common Stock worth $38M.
- Deerfield Management's largest Q2 2016 buy was Syros Pharmaceuticals, Inc. Common Stock: 209,522 shares worth $38M.
- Deerfield Management added most to Adeptus Health Inc in Q2 2016, an estimated $38.6M increase.
- Deerfield Management's biggest Q2 2016 reduction was Aetna Inc, cutting an estimated $25.9M.
- Deerfield Management fully exited GSK in Q2 2016, selling an estimated $67.9M.
- Deerfield Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2016.
- Deerfield Management opened 21 new positions and closed 19 in Q2 2016.
- Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $2.54B.
Based on Deerfield Management's 13F filing for Q2 2016, filed 15 Aug 2016.